We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Therapeutic Interaction of Apatinib and Chidamide in T-cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis.
- Authors
Zhong, Mengya; Lin, Fusheng; Jiang, Yuelong; Pan, Guangchao; Tan, Jinshui; Zhou, Hui; Lai, Qian; Chen, Qinwei; Deng, Manman; Zha, Jie; Xu, Bing
- Abstract
T-cell acute lymphoblastic leukemia (T-ALL) shows poor clinical outcome and has limited therapeutic options, indicating that new treatment approaches for this disease are urgently required. Our previous study demonstrated that apatinib, an orally selective VEGFR-2 antagonist, is highly effective in T-ALL. Additionally, chidamide, a histone deacetylase inhibitor, has proven to be cytotoxic against T-ALL in preclinical and clinical settings. However, whether the therapeutic interaction of apatinib and chidamide in T-ALL remains unknown. In this study, apatinib and chidamide acted additively to decrease cell viability and induce apoptosis in T-ALL in vitro. Notably, compared with apatinib or chidamide alone, the combinational regimen was more efficient in abrogating the leukemia burden in the spleen and bone marrow of T-ALL patient-derived xenograft (PDX) models. Mechanistically, the additive antileukemia effect of apatinib and chidamide was associated with suppression of mitochondrial respiration and downregulation of the abundance levels of several rate-limiting enzymes that are involved in the citric acid cycle and oxidative phosphorylation (OXPHOS). In addition, apatinib enhanced the antileukemia effect of chidamide on T-ALL via activation of the mitochondria-mediated apoptosis pathway and impediment of mitochondrial biogenesis. Taken together, the study provides a potential role for apatinib in combination with chidamide in the management of T-ALL and warrants further clinical evaluations of this combination in patients with T-ALL.
- Subjects
MITOCHONDRIA formation; LYMPHOBLASTIC leukemia; T cells; ACUTE leukemia; KREBS cycle
- Publication
Journal of Personalized Medicine, 2021, Vol 11, Issue 10, p977
- ISSN
2075-4426
- Publication type
Article
- DOI
10.3390/jpm11100977